<DOC>
	<DOCNO>NCT01591343</DOCNO>
	<brief_summary>Safety study Depigoid vaccine Dermatophagoides pteronyssinus 50 % Dermatophagoides pteronyssinus / 50 % Dermatophagoides farinae ( 500 DPP/ml ) , treat allergic rhinitis rhinoconjunctivitis without asthma . Primary variable : number subject [ % ] experience least one immediate delay systemic reaction EAACI grade 2 high 4-month treatment period .</brief_summary>
	<brief_title>Safety Study Depigoid Vaccine Dermatophagoides Pteronyssinus 50 % Dermatophagoides Pteronyssinus / 50 % Dermatophagoides Farinae ( 500 DPP/ml ) , Treat Allergic Rhinitis Rhinoconjunctivitis With Without Asthma .</brief_title>
	<detailed_description>Investigator ( ) : Approximately 10 study center ( allergy service ) Spain Planned study period : MAY 2012 ( first subject ) - MAR 2013 ( last subject ) Objectives : Primary objective : evaluate safety 4-month treatment extract Depigoid® Dermatophagoides pteronyssinus mixture 50 % Dermatophagoides pteronyssinus 50 % Dermatophagoides farinae concentration 500 DPP/ml administer follow rush build-up regimen . Secondary objective : assess subject ' immunologic response treatment . Study design : This prospective , non-randomized , uncontrolled , open-label safety study . When first 29 subject complete study , interim analysis conduct check whether number systemic reaction subject predefined limit . Planned number subject : 103 subject total . Medical condition disease investigation : Allergic rhinitis rhinoconjunctivitis , without mild persistent intermittent asthma . Test product , dose mode administration : Depigoid® D. pteronyssinus Depigoid® 50 % D. pteronyssinus / 50 % D. farinae ( 500 DPP/ml ) . Dose : Week 0 : 0.2 ml follow 0.3 ml 30 min Week 4 , 8 , 12 , 16 : 0.5 ml Mode administration : subcutaneous injection Duration treatment : 16 week . Criteria evaluation : Safety : Local systemic adverse reaction ( EAACI classification ) ; adverse event . Efficacy : Immunologic response treatment . Statistical method : Primary variable : number subject [ % ] experience least one immediate delay systemic reaction EAACI grade 2 high 4-month treatment period . Analysis primary variable : exact binomial test</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Men woman 18 55 year age ( inclusive ) . Individuals suffer symptom allergic rhinoconjunctivitis rhinitis least preceding year without symptom mild persistent intermittent allergic asthma control dose less equal 400 µg/day budesonide equivalent cause clinically relevant sensitization house dust mite ( Dermatophagoides pteronyssinus Dermatophagoides pteronyssinus Dermatophagoides farinae ) . The IgEmediated sensitization demonstrate mean follow : medical history IgE specific house dust mite ( D. pteronyssinus D. pteronyssinus D. farinae ) CAP RAST ≥ 2 positive skin prick test . A skin prick test consider positive produce wheal least 3 mm accord large diameter . Asthmatic patient must stable stable inhaled steroid dose within 6 week prior visit 1 throughout study . Any contraindication treatment allergen specific immunotherapy . Forced expiratory volume 1 ( FEV1 ) peak expiratory flow ( PEF ) value &lt; 80 % predict normal value . Allergy symptom due sensitization pollens perennial allergen ( mold , epithelium ) . Subjects typical symptom coallergens tree pollen , grass weed , fungi animal epithelial cell participate study . Patients sensitize pollen specific IgE CAP RAST &lt; 2 include study provide present symptom consequence sensitization . Patients sensitize animal epithelia present symptom participate study provide expose allergen sensitize , even though present specific IgE CAP RAST ≥ 2 . If expose animal question , subject must specific IgE CAP RAST &lt; 2 order participate study . Asthma require dose &gt; 400 µg/day Budesonide equivalent , without longlasting beta2 agonist , reach control accord Global Initiative Asthma ( GINA 2010 ) . Patients non control bronchial asthma within 3 month prior Visit 1 . Patients asthma treat systemic steroid within 3 month prior V1 . Patients hospital admission due asthma exacerbation within 1 year prior V1 Acute chronic inflammatory infectious disease airway . Chronic structural disease respiratory system ( example , emphysema bronchiectasis ) . Immune system disease , autoimmune disease immunodeficiency . Any disease involve contraindication use adrenaline ( example , hyperthyroidism ) . Serious uncontrolled disease involve risk subject participate study , include follow example : heart failure , serious uncontrolled respiratory disease , endocrine disease , clinically relevant liver kidney diseases hematological disease . Malignant disease activity last 5 year . Clinically significant anomaly laboratory parameter vital sign could involve risk increase subject . Excessive consumption alcohol , drug medication precede year . Serious psychiatric , psychological neurological disorder . Use immunotherapy allergenic extract storage house dust mite last 5 year . Systemic topical treatment betablocker drug . Treatment substance interfere immune system 2 week visit 2 . Use psychotropic antidepressant substance . Use systemic corticosteroid 3 month visit 1 . Immunization prophylactic ( bacterial viral ) vaccine within 7 day visit 2 . ( Prophylactic vaccine allow administration IMP period provide administer least one week immunotherapy next immunotherapy dose administer least 14 day later ) . Participation subject another clinical trial 30 day visit 2 . Subjects already participate clinical trial . Subjects go donate stem cell , blood , organs bone marrow course study . Female subject pregnant nursing woman positive pregnancy test visit 1 2 . Women childbearing potential use highly effective method birth control . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly , implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomize partner . Female patient consider childbearing potential unless surgically sterilize hysterectomy bilateral tubal ligation , postmenopausal least two year . No write inform consent upon enrolment . Not willing give consent transmission personal `` pseudonymised '' data . Subjects unable comply requirement study opinion investigator participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Specific immunotherapy</keyword>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
	<keyword>Asthma</keyword>
</DOC>